Can a simple scan predict if cancer drugs will work?
NCT ID NCT03832348
Summary
This study aimed to see if early PET scans could predict how well a standard immunotherapy drug (pembrolizumab) would work for advanced lung cancer. Researchers followed 40 patients with advanced lung cancer who were already scheduled to receive this treatment. They performed PET scans before the first three treatments to see if early changes in the scans could forecast the patient's response three months later.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU
Rouen, 76000, France
-
Centre Henri Becquerel
Rouen, 76000, France
Conditions
Explore the condition pages connected to this study.